Life sciences regulation in India: the need for evolution
The life sciences industry has traditionally been classified as consisting of pharmaceuticals and healthcare. The area of biotechnology has evolved as an important contributor to the pharmaceutical, agricultural and industrial sciences industries, and serves both medical and non-medical markets. The medical market includes human therapeutics, human diagnostics as well as applications in veterinary medicine. Within the non-medical markets there is a split between agriculture and industrial applications.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.
20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.
6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.